Antisense & RNAi Therapeutics Market Report 2026

The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.93 billion in 2025 to $2.17 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to early adoption of antisense therapies, initial rnai research breakthroughs, development of oligonucleotide synthesis techniques, growing demand for targeted therapeutics, investments in biotech research.

The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancements in delivery technologies, expansion of precision medicine, integration with ai-driven drug discovery, increasing rnai-based clinical trials, rising healthcare investments in emerging markets. Major trends in the forecast period include targeted gene silencing, novel delivery mechanisms, personalized therapeutics, nucleic acid stabilization techniques, regulatory & clinical advancements.

The rising prevalence of coronary artery disease, neurodegenerative disorders, and infectious diseases is expected to drive the growth of the antisense and RNAi therapeutics market. Gene-silencing approaches, including RNA interference (RNAi) and antisense oligonucleotides, are employed to treat various neurodegenerative conditions by correcting or suppressing mutant gene expression. For instance, in January 2024, the American Heart Association, a US-based organization, reported that the age-adjusted death rate from cardiovascular diseases rose to 233.3 per 100,000, marking a 4% increase from the previous year. This trend highlights the growing burden of cardiovascular and related diseases, fueling demand for advanced gene-targeted therapies.

Major companies in the antisense and RNAi therapeutics market are pursuing strategic collaborations and partnerships to accelerate innovation and maintain competitiveness. For example, in January 2023, Orbit Discovery Limited, a US-based peptide discovery company, partnered with SanegeneBio Inc., a UK-based RNAi therapeutics developer, to advance tissue-specific delivery of RNA therapeutics through hit identification and cell-based internalization studies. Orbit’s peptide display technology enables rapid discovery of effective therapeutic leads for gene knockdown.

In July 2023, Alnylam, a US-based RNAi therapeutics company, entered a strategic partnership with Roche AG, Switzerland, to co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic for hypertension in patients with high cardiovascular risk. This collaboration leverages Alnylam’s RNAi expertise and Roche’s commercialization capabilities to expand treatment options in cardiovascular disease management.

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical.

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in the antisense & rnai therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antisense & rnai therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the antisense & rnai therapeutics market by increasing the cost of imported oligonucleotides, delivery devices, and laboratory equipment, thereby creating supply chain disruptions. The impact is most pronounced in regions like north america and europe, which heavily rely on imported biotech components. Segments such as rna interference (rnai) therapeutics and antisense oligonucleotides face higher production costs, while nascent companies may experience delayed product launches. However, tariffs have incentivized local manufacturing and innovation in delivery systems, creating opportunities for domestic production and cost optimization.

The antisense & rnai therapeutics market research report is one of a series of new reports that provides antisense & rnai therapeutics market statistics, including antisense & rnai therapeutics industry global market size, regional shares, competitors with a antisense & rnai therapeutics market share, detailed antisense & rnai therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & rnai therapeutics industry. This antisense & rnai therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antisense therapy involves the selective, sequence-specific suppression of gene expression using single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and leads to sequence-specific degradation of target single-stranded mRNAs.

The main technologies in antisense and RNAi therapeutics include RNA interference and antisense RNA. RNA interference is a conserved biological mechanism that responds to double-stranded RNA, providing resistance to both endogenous parasitic and exogenous pathogenic nucleic acids while regulating protein-coding gene expression. Routes of administration include pulmonary delivery, intravenous injection, intradermal injection, intraperitoneal injection, topical delivery, and others. These therapies are applied for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and other conditions.

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.